These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 16955437)
41. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Kim TS; Lim HK; Lee JY; Kim DJ; Park S; Lee C; Lee CU Neurosci Lett; 2008 May; 436(2):196-200. PubMed ID: 18378084 [TBL] [Abstract][Full Text] [Related]
42. APOE and cytokines as biological markers for recovery of prevalent delirium in elderly medical inpatients. Adamis D; Treloar A; Martin FC; Gregson N; Hamilton G; Macdonald AJ Int J Geriatr Psychiatry; 2007 Jul; 22(7):688-94. PubMed ID: 17203511 [TBL] [Abstract][Full Text] [Related]
43. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Abdullah L; Paris D; Luis C; Quadros A; Parrish J; Valdes L; Keegan AP; Mathura V; Crawford F; Mullan M Neurosci Lett; 2007 Nov; 428(2-3):53-8. PubMed ID: 17964720 [TBL] [Abstract][Full Text] [Related]
44. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Motta M; Imbesi R; Di Rosa M; Stivala F; Malaguarnera L Immunol Lett; 2007 Nov; 114(1):46-51. PubMed ID: 17949824 [TBL] [Abstract][Full Text] [Related]
45. A prospective study of the association of cerebrospinal fluid monoamine metabolite levels with lethality of suicide attempts in patients with bipolar disorder. Sher L; Carballo JJ; Grunebaum MF; Burke AK; Zalsman G; Huang YY; Mann JJ; Oquendo MA Bipolar Disord; 2006 Oct; 8(5 Pt 2):543-50. PubMed ID: 17042827 [TBL] [Abstract][Full Text] [Related]
46. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM Free Radic Res; 2008 Feb; 42(2):162-70. PubMed ID: 18297609 [TBL] [Abstract][Full Text] [Related]
48. Peripheral serotonin in Alzheimer's disease. Kumar AM; Sevush S; Kumar M; Ruiz J; Eisdorfer C Neuropsychobiology; 1995; 32(1):9-12. PubMed ID: 7566524 [TBL] [Abstract][Full Text] [Related]
49. Reliability and validity of the Japanese version of the Dysexecutive Questionnaire (DEX) in Alzheimer's disease: validation of a behavioral rating scale to assess dysexecutive symptoms in Japanese patients with Alzheimer's disease. Shinagawa Y; Nakaaki S; Hongo J; Murata Y; Sato J; Matsui T; Tatsumi H; Akechi T; Furukawa TA Int J Geriatr Psychiatry; 2007 Oct; 22(10):951-6. PubMed ID: 17299806 [TBL] [Abstract][Full Text] [Related]
50. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease. Tei E; Yamamoto H; Watanabe T; Miyazaki A; Nakadate T; Kato N; Mimura M Growth Horm IGF Res; 2008 Feb; 18(1):47-54. PubMed ID: 17714966 [TBL] [Abstract][Full Text] [Related]
51. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225 [TBL] [Abstract][Full Text] [Related]
52. Serotonergic influences on life-history outcomes in free-ranging male rhesus macaques. Howell S; Westergaard G; Hoos B; Chavanne TJ; Shoaf SE; Cleveland A; Snoy PJ; Suomi SJ; Dee Higley J Am J Primatol; 2007 Aug; 69(8):851-65. PubMed ID: 17330868 [TBL] [Abstract][Full Text] [Related]
53. Enzymes of drug metabolism during delirium. White S; Calver BL; Newsway V; Wade R; Patel S; Bayer A; O'Mahony MS Age Ageing; 2005 Nov; 34(6):603-8. PubMed ID: 16267186 [TBL] [Abstract][Full Text] [Related]
54. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Jones RW; Kivipelto M; Feldman H; Sparks L; Doody R; Waters DD; Hey-Hadavi J; Breazna A; Schindler RJ; Ramos H; Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958 [TBL] [Abstract][Full Text] [Related]
55. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598 [TBL] [Abstract][Full Text] [Related]
56. Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease. Chuo LJ; Sheu WH; Pai MC; Kuo YM Dement Geriatr Cogn Disord; 2007; 23(4):251-7. PubMed ID: 17310123 [TBL] [Abstract][Full Text] [Related]
58. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Baranowska-Bik A; Bik W; Wolinska-Witort E; Martynska L; Chmielowska M; Barcikowska M; Baranowska B Neuro Endocrinol Lett; 2008 Feb; 29(1):75-9. PubMed ID: 18283248 [TBL] [Abstract][Full Text] [Related]
59. Influence of the Pro12Ala polymorphism of PPAR-gamma on age at onset and sRAGE levels in Alzheimer's disease. Yao L; Li K; Zhang L; Yao S; Piao Z; Song L Brain Res; 2009 Sep; 1291():133-9. PubMed ID: 19631630 [TBL] [Abstract][Full Text] [Related]